Cochlear shares climb 16% as company faces competition in totally implantable implants

Cochlear Ltd's shares rebounded 16% on Tuesday, reaching AU$123.20 after a sharp decline earlier in the year. The stock remains down about 53% for 2026 and 59% over the past 12 months. The rally follows a profit‑guidance cut for FY2026 to $290‑$330 million, down from the previously forecast $435‑$460 million, after weaker demand and Middle‑East supply disruptions.

The Australian hearing‑implant maker still controls roughly half of the global cochlear‑implant market and sees a large untapped patient base. However, UBS highlighted growing competitive pressure in the emerging totally implantable cochlear implant (TICI) segment. Envoy Medical, a US‑based firm, reported trial results that could rival Cochlear's TICI device, potentially giving Envoy a first‑mover advantage. UBS maintained a neutral stance on Cochlear with a target price of $106.

While the competition is not expected to affect near‑term earnings, it could influence Cochlear's longer‑term growth trajectory. The company continues its own TICI trial, and other players such as MED‑El are also advancing in the space.